ANDA 210017, held by Jubilant Cadista. Drospirenone; Ethinyl Estradiol.
As of Nov 15, 2026, ANDA 210017 (Drospirenone And Ethinyl Estradiol), held by Jubilant Cadista, was first approved by FDA on Sep 10, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Drospirenone And Ethinyl Estradiol3MG;0.03MG ยท tablet;oral-28 | Drospirenone; Ethinyl Estradiol | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
